Elite control of HIV infection: implications for vaccine design
about
Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccinesDendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapyHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentObstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.HIV-1 vaccine clinical trials: the Brazilian experience.Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virusIgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion.Dendritic cells restore CD8+ T cell reactivity to autologous HIV-1Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181.Short communication: Lack of immune response in rapid progressor morphine-dependent and SIV/SHIV-infected rhesus macaques is correlated with downregulation of TH1 cytokines.Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design.Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques.Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.The immune response during acute HIV-1 infection: clues for vaccine development.Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllersTransmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study.No acquisition: a new ambition for HIV vaccine development?Higher Frequency of NK and CD4+ T-Cells in Mucosa and Potent Cytotoxic Response in HIV Controllers.Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenImmunogenetics of HIV disease.Decoupling activation and exhaustion of B cells in spontaneous controllers of HIV infection.Elevated hypermutation levels in HIV-1 natural viral suppressors.Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.New clinical trial designs for HIV vaccine evaluation.Some unmet challenges in the immunology of viral infections.An evaluation of HIV elite controller definitions within a large seroconverter cohort collaborationDivergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.Dynamic interplay between viral adaptation and immune recognition during HIV-1 infection.An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine?Gene array studies in HIV-1 infectionThe genetic basis of resistance to HIV infection and disease progression.A systematic review of definitions of extreme phenotypes of HIV control and progression.Update on antiretroviral treatment during primary HIV infection.
P2860
Q26827712-E513CA4F-70F0-4A96-B582-612CC482E0DBQ28475576-5D568BE3-A4F3-4F4A-8CE8-A3259847BA37Q30355260-3228BA68-3AFF-4C1C-BA24-C1BDC554696CQ30378897-838AC683-C35F-4085-899A-865887B500DBQ30379462-FE125FE3-523A-492D-9676-236DB5DF6F7BQ33547403-D0C3D73A-9257-4D62-84CF-4908FC0E080AQ33769283-221C757B-01AC-4233-9B24-62EE82663E82Q33827771-17BB253A-DCD9-4D41-87DF-27528590E12BQ33987485-492764C7-A256-4C14-81B9-44726852EB86Q34059416-8354810B-0A15-447F-9E46-CA2CAE257D5BQ34150457-D0CA0B0D-D47B-4854-A98D-DCC8829C47C7Q34213818-117C8B08-E3D4-4052-A847-C1F9788915C4Q34334803-7D9F4836-2D30-4D6C-8902-01D7F3405B30Q34556871-BBA188D7-755A-4340-B2D0-AB75BB4E429AQ34574409-17DF4C53-C811-4BB4-8215-69A4D3468313Q34614862-87286018-7C17-4A26-A6B4-16100DCD2F57Q34625953-A19C7993-DA48-4437-BDD1-A4C464B25632Q34874985-49D2E71C-5371-4ADC-9DF6-AC07432D36D5Q34950830-BB403FDC-96FE-427F-9275-985C5BB16A15Q34979376-ADB4F092-1E9D-47E1-B1B6-8E7CD3464652Q35007339-53F7BC66-90C3-45AF-B924-028CA25E5F34Q35121777-901000F9-0E64-43BE-B333-5F464D80AE96Q35534563-8F765A2E-27A6-4299-9BAD-3A842CB8BE8AQ35751335-C969DF9C-7459-49B1-8773-CB9C2BFCC9EEQ35862305-80E7BD0F-B57E-4170-9E63-8596CE114147Q36456190-84564008-8FE8-4BD7-84A8-BAA9CA120C0CQ36989456-1837A298-720A-411C-ADD4-CB201304C894Q37059419-CEC69DD0-3051-4393-ABB5-D277CFFDBA43Q37145307-FF497154-886A-47D2-A918-3ACCED513A04Q37381097-CB608810-AB90-4E6F-9030-FE49EECC386BQ37412300-E83E7314-F545-477A-8906-E1FF89B97E38Q37448238-E205B671-1DD0-4507-83FB-AE39F98139DBQ37525462-6ED46E72-5F4E-40B1-AE22-DC82EC0928BCQ37643973-7D6E3BF0-7897-47E2-96A3-F04032F4408AQ37825838-E4537E71-71F3-4DAE-BBEF-7BE8EFA897EDQ37845847-F54CBCC0-88FA-4EF9-A836-B30312727BD8Q37970040-A4C616EB-5628-4D1C-966B-8B0C58C30D6DQ38096026-90778504-4C71-4CA0-BDF2-07BC06EB2442Q38154750-C41F1A33-7399-42E8-ABFE-EF45AD4AD63AQ38209874-6341CE30-8138-4180-A6F1-51B763FD74EC
P2860
Elite control of HIV infection: implications for vaccine design
description
article
@en
im Januar 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2009
@uk
name
Elite control of HIV infection: implications for vaccine design
@en
Elite control of HIV infection: implications for vaccine design
@nl
type
label
Elite control of HIV infection: implications for vaccine design
@en
Elite control of HIV infection: implications for vaccine design
@nl
prefLabel
Elite control of HIV infection: implications for vaccine design
@en
Elite control of HIV infection: implications for vaccine design
@nl
P2093
P2860
P1476
Elite control of HIV infection: implications for vaccine design
@en
P2093
A C Rothchild
B D Walker
P2860
P356
10.1517/14712590802571928
P407
P577
2009-01-01T00:00:00Z